An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 730 participants.

Also called NCT03354273

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 730 participants (enrolled count) (from the registry)
Sponsor
  • GE Healthcare Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03354273
  • EudraCT 2017-005011-14
Other papers using this trial's data
  • Flurpiridaz F-18 PET Myocardial Perfusion Imaging in Patients With Suspected Coronary Artery Disease Journal of the American College of Cardiology, 2023-10-17 DOI, PubMed 37821170
  • Improved assessment of coronary artery disease in obese patients with flurpiridaz-18F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2026-07 DOI, PubMed 42128226, PMC13262012 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Finland, France, Germany, Netherlands, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03354273. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-06-05 (actual); primary completion 2022-05-05 (actual). Results posted on 2023-07-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
Intervention (Drug)
PET MPI
Intervention (Drug)
SPECT MPI
Intervention (Drug)
Pharmacological stress agents
Lead sponsor
GE Healthcare (class: industry)
Collaborator
Pharmaceutical Product Development, (PPD) LLC (class: industry)

Record details

Record id
cardio:ct-nct03354273
Content hash
da0d9a0cd3549d504a4f8b12f03f4241d695fe84890c9d0a923f286f59fed660